Search results for "reactions"

showing 10 items of 631 documents

First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction

2005

BACKGROUND: Serum biochemical markers [free betahCG (fbetahCG); pregnancy-associated plasma protein-A (PAPP-A)] used in first trimester Down's syndrome screening have not been fully investigated in pregnancies achieved by assisted reproduction techniques. We present data on pregnancies conceived by all types of assisted reproduction techniques, including pregnancies following ovum donation (OD) and a large sample by ICSI. METHODS: First trimester Down's syndrome screening was performed in 1054 normal singleton pregnancies: natural conception (n = 498), ovulation induction (OS, n = 97), IVF (n = 47), ICSI (n = 222) and OD (n = 190). RESULTS: No differences in maternal levels of fbetahCG and …

Down syndromemedicine.medical_specialtyReproductive Techniques AssistedPregnancy-associated plasma protein Amedicine.medical_treatmentPrenatal diagnosisBiologyPreimplantation genetic diagnosisEmbryo cryopreservationPregnancyPrenatal DiagnosismedicineHumansChorionic Gonadotropin beta Subunit HumanFalse Positive ReactionsGynecologyPregnancyurogenital systemObstetricsRehabilitationReproducibility of ResultsObstetrics and GynecologyGestational agemedicine.diseasePregnancy Trimester FirstReproductive MedicineFemaleOvulation inductionDown SyndromeBiomarkersHuman Reproduction
researchProduct

A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital

1996

1A total of 512 consecutive paediatric hospital admissions of children 2 years old or less were evaluated to assess the extent and pattern of admission caused by suspected adverse drug reactions (ADRs). The proportion of suspected ADRs related to hospital admissions was 4.3%. 2The organ-systems most commonly implicated were the central nervous system (40.5%), digestive system (16.7%), and skin and appendages (14.3%). Together, they accounted for 71.5% of admissions attributed to ADRs. The most common clinical manifestations inducing admission were convulsions (4 cases), dizziness (4), vomiting (3), and tremor, fever, itching and apnoea (2 cases each). 3The four classes of drugs most frequen…

Drug UtilizationMalemedicine.medical_specialtyPediatricsDrug-Related Side Effects and Adverse ReactionsEpidemiologyPharmacovigilanceMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyPharmacologybusiness.industryGuaiphenesinInfant NewbornInfantOdds ratioOriginal ArticlesHospitalizationChild PreschoolVomitingItchingFemalemedicine.symptombusiness
researchProduct

Immunotoxicity of Therapeutic Antibodies and Nanoparticles.

2020

Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining…

DrugCytotoxicity ImmunologicDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectImmunologyContext (language use)BioengineeringMonoclonal antibodyAntibodiesTargeted therapyImmunomodulationImmune systemImmunology and AllergyMedicineAnimalsHumansAdverse effectmedia_commonbusiness.industryImmunosuppressionTolerabilityDrug DesignImmune SystemImmunologyNanoparticlesbusinessCritical reviews in immunology
researchProduct

Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.

2007

The pharmaceutical industry is committed to marketing safer drugs with fewer side effects, predictable pharmacokinetic properties and quantifiable drug-drug interactions. Drug metabolism is a major determinant of drug clearance and interindividual pharmacokinetic differences, and an indirect determinant of the clinical efficacy and toxicity of drugs. Progressive advances in the knowledge of metabolic routes and enzymes responsible for drug biotransformation have contributed to understanding the great metabolic variations existing in human beings. Phenotypic as well genotypic differences in the expression of the enzymes involved in drug metabolism are the main causes of this variability. How…

DrugDiclofenacDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectBiologyPharmacologyIn Vitro TechniquesToxicologyModels BiologicalPharmacokineticsCytochrome P-450 Enzyme SystemIn vivoGenetic variationHumansDrug InteractionsPharmacokineticsBiotransformationCells Culturedmedia_commonMolecular StructureAnti-Inflammatory Agents Non-SteroidalCytochrome P450Genetic VariationGeneral MedicineIn vitroPharmaceutical PreparationsToxicityInactivation Metabolicbiology.proteinHepatocytesDrug metabolismMetabolic Networks and PathwaysChemico-biological interactions
researchProduct

Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project.

2010

The 6th European Framework Programme project LIINTOP was specifically raised to optimise and provide established protocols and experimental in vitro models for testing intestinal and liver absorption, metabolism and toxicity of molecules of pharmacological interest. It has been focused on some of the most promising existing liver and intestine in vitro models with the aim of further improving their performance and thus taking them to a pre-normative research stage. Regarding the specific area of the liver, a first basic approach was the optimisation of in vitro hepatic models and the development and optimisation of in vitro approaches for toxicity screening. New advanced technologies have b…

DrugDrug-Related Side Effects and Adverse ReactionsMechanism (biology)media_common.quotation_subjectMechanism basedGeneral MedicineComputational biologyPharmacologyBiologyToxicologyModels BiologicalIn vitroLiverChemical agentsToxicity TestsMolecular targetsScreening methodAnimalsHumansChemical and Drug Induced Liver InjurySelection (genetic algorithm)media_commonToxicology in vitro : an international journal published in association with BIBRA
researchProduct

Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

2016

Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM).The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed. By integrating TDM studies with the information on in vitro metabolism studies, case report/series and prospective studies, a table is provided to manage average SGA patients taking inducers or inhibitors by using TDM and/or …

DrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjecttherapeutic drug monitoringAdministration OralPharmacologyToxicology030226 pharmacology & pharmacyDrug interactions03 medical and health sciences0302 clinical medicinePharmacokineticsinhibitorsMedicineHumansProspective cohort studyClozapinemedia_commonLurasidoneinducersPharmacologyRisperidonemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrysecond-generation antipsychoticsGeneral MedicineDrug interactions; inducers; inhibitors; pharmacokinetics; second-generation antipsychotics; therapeutic drug monitoring030227 psychiatryTherapeutic drug monitoringQuetiapineAntidepressive Agents Second-GenerationDrug Monitoringbusinesspharmacokineticsmedicine.drugAntipsychotic Agents
researchProduct

Detection of  9-Tetrahydrocannabinol and Amphetamine-Type Stimulants in Oral Fluid Using the Rapid Stat  Point-of-Collection Drug-Testing Device

2010

The Rapid Stat assay, a point-of-collection drug-testing device for detection of amphetamines, cannabinoids, cocaine, opiates, methadone, and benzodiazepines in oral fluid, was evaluated for cannabis and amphetamine-type stimulants. The Rapid Stat tests (n = 134) were applied by police officers in routine traffic checks. Oral fluid and blood samples were analyzed using gas chromatography-mass spectrometry (GC-MS) for Delta(9)-tetrahydrocannabinol, amphetamine, methamphetamine, methylenedioxymethamphetamine, methylenedioxyethylamphetamine, and methylenedioxyamphetamine. The comparison of GC-MS analysis of oral fluid with the Rapid Stat results for cannabis showed a sensitivity of 85%, a spec…

DrugMarijuana AbuseSalivaN-Methyl-34-methylenedioxyamphetamineHealth Toxicology and Mutagenesismedia_common.quotation_subjectmedicine.medical_treatmentAmphetamine-Related DisordersPharmacologyToxicologySensitivity and SpecificityGas Chromatography-Mass SpectrometryMethamphetamineAnalytical ChemistryPredictive Value of TestsmedicineHumansEnvironmental ChemistryFalse Positive ReactionsDronabinolSalivaAmphetamineFalse Negative Reactionsmedia_commonImmunoassayChemical Health and SafetyChromatographybiologyChemistryAmphetaminesSolid Phase ExtractionMethamphetaminebiology.organism_classificationSubstance Abuse DetectionAmphetamineCannabinoidCannabisGas chromatography–mass spectrometrymedicine.drugMethadoneJournal of Analytical Toxicology
researchProduct

Drug-induced oral lichenoid reactions: a literature review

2010

The terms oral lichenoid reactions or oral lichenoid lesions refer to lesions histologically and clinically similar to oral lichen planus, though with the particularity that in these cases the underlying cause is identifiable. In addition, these lesions are described according to the causal factor involved, including alterations resulting from direct contact with dental restoration materials, drug-related lesions, and lesions associated to graft-versus-host disease. Drug-induced oral lichenoid reactions or oral lichenoid lesions were first cited in 1971 by Almeyda and Levantine. Since then, many drug substances have been associated with such lesions. The most common agents are nonsteroidal …

DrugPathologymedicine.medical_specialtyNonsteroidalbiologybusiness.industrymedia_common.quotation_subjectAngiotensin-converting enzymeOdontologíamedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludchemistry.chemical_compoundstomatognathic diseaseschemistryUNESCO::CIENCIAS MÉDICASbiology.proteinMedicineLichenoid reactionsOral lichen planusbusinessGeneral DentistryLichenoid lesionsmedia_common
researchProduct

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

2010

Epidermal necrolysis (EN)--either Stevens-Johnson syndrome (SJS) or toxic EN (TEN)--is a severe drug reaction. We constructed and evaluated a specific algorithm, algorithm of drug causality for EN (ALDEN), in order to improve the individual assessment of drug causality in EN. ALDEN causality scores were compared with those from the French pharmacovigilance method in 100 cases and the case-control results of the EuroSCAR study. Scores attributed by ALDEN segregated widely. ALDEN pointed to a "probable" or "very probable" causality in 69/100 cases as compared to 23/100 with the French method (P < 0.001). It scored "very unlikely" causality for 64% of medications vs. none with the French metho…

DrugTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectRecurrenceEpidermal necrolysisPharmacovigilanceProduct Surveillance PostmarketingHumansMedicinePharmacology (medical)Drug reactionProbabilitymedia_commonPharmacologybusiness.industryReproducibility of ResultsStevens johnsonmedicine.diseaseCausalityToxic epidermal necrolysisEuropePharmaceutical PreparationsCase-Control StudiesStevens-Johnson SyndromeCase control analysisFrancebusinessAlgorithmAlgorithmsClinical Pharmacology &amp; Therapeutics
researchProduct

Adverse drug reactions in the oral cavity

2012

Several drugs may have a number of adverse reactions (ADRs) involving the oro-facial region. The dose of the drug and the time required for the reaction to take place are relevant parameters; nonetheless, ADRs mechanisms are not always known and ADRs are not always predictable since aspects other than drug pharmacodynamics and/or pharmacokinetics, as well as various interacting variables contribute to the final outcome. All tissues and many functions of the oral cavity can be affected. In particular, salivary function is fre- quently involved and hypo-salivation is the main manifestation; several mucosal lesions with different morphology (ulcerations, vesiculo- bullous lesions, white lesion…

Drugdrug pharmacodynamicosteonecrosimedicine.medical_specialtyTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectSettore MED/50 - Scienze Tecniche Mediche Applicatehypo-salivationPigmentationsPharmacologyOral cavitymucosal lesionDrug withdrawalPharmacokineticsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryHumansMedicinemedical liabilityDrug reactionpharmacokineticmedia_commonPharmacologyMouthDose-Response Relationship Drugbusiness.industrybisphosphonates.Mucosal lesionsMouth MucosadrugAdverse reactionmedicine.diseaseDermatologyPharmaceutical PreparationsTastePharmacodynamicsoral cavityadverse drug reaction oral cavityMouth DiseasesSalivationbusiness
researchProduct